Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain
Superficial Urinary Bladder Carcinoma
Explore 3 assets in Superficial Urinary Bladder Carcinoma →Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
vaccine
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03711032CT.gov Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Superficial Urinary Bladder Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain (this asset) | Merck Sharp & Dohme LLC | P3 | B · 59 |
| Pembrolizumab | Merck Sharp & Dohme LLC | P3 | B |
| Tyra-300 | Tyra Biosciences, Inc | P1/2 | CCC |
| Pvsripo (Chimeric Poliovirus (Pv), Consisting Of The Type-1 Sabin Vaccine Strain Carrying A Foreign Internal Ribosome Entry Site (Ires) From Human Rhinovirus Type-2) (Hrv2) | Istari Oncology, Inc. | P1/2 | CC |
Other indications for Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alzheimer Disease | — | P2 | BB · 64 |
| Metastatic Melanoma | — | P2/3 | B · 61 |
| Cutaneous Melanoma | — | P2/3 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain in Superficial Urinary Bladder Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bacillus-calmette-guerin-live-antigen-unspecified-substrain-superficial-urinary-bladder-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →